Air date: Wednesday, December 15, 2010, 3:00:00 PM
Time displayed is Eastern Time, Washington DC Local
Category: Wednesday Afternoon Lectures
Description: Gene therapy has the potential to reverse disease or prevent further deterioration of vision in patients with incurable inherited retinal degeneration. The demonstration of safe and stable recovery of retinal/visual function in 12 children and adults with Leber congenital amaurosis (LCA) due to RPE65 mutations in a trial being carried out at The Children's Hospital of Philadelphia (CHOP), and encouraging results from four other clinical trials for LCA-RPE65 provide great hope for people with other more common blinding diseases. This presentation will describe the animal studies that led to the clinical trials and the latest safety and efficacy results in the LCA-RPE65 clinical trial being held at CHOP. This Phase 1-2 study is now 3 years past initiation. In addition, it will describe some of the challenges presented by the nature of the targeted disease itself, hurdles that have been navigated in order to conduct the study, and issues of importance for eventual approval of gene augmentation as a therapy for LCA and other blinding diseases.

The NIH Director's Wednesday Afternoon Lecture Series includes weekly scientific talks by some of the top researchers in the biomedical sciences worldwide.
Author: Jean Bennett, M.D., Ph.D., University of Pennsylvania
Runtime: 00:56:17
Permanent link: [ Ссылка ]

свернуть